Thu 3/21/2019 23:50 ET
DJIA25962.51218.090.84%TELCO169.572.311.36%GOLD1308.651.310.10%Shanghai3077.1424.000.78%
S&P 5002854.8831.121.09%BANKS427.326.321.48%OIL59.870.110.18%BITCOIN3998.862.000.05%
NASDAQ7838.96111.311.42%PHARM583.633.150.54%US/EU1.140.000.00%Futures2857.385.140.18%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Achaogen - AKAO   

Return Top | Return List | Reply Thread | Search | Add AKAO | Ignore AKAO
From: singhtelecom (Rep: 959)Date: 2017-03-29 11:59:08
Forum: Achaogen - Thread #673917298Msg #150 - Part 1/4 (Rec: 0)
PCYC ecx CEO ROBERT DUGGAN took stake
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User singhtelecom: Reward | Watch | Ignore

From: blacksheep (Rep: 331) reply to singhtelecomDate: 2017-03-29 13:45:02
Forum: Achaogen - Thread #673917298Msg #151 - Part 2/4 (Rec: 0)
Re: PCYC ecx CEO ROBERT DUGGAN took stake=> Haven't sold any and have converted all Mar calls into shares.
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User blacksheep: Reward | Watch | Ignore

From: blacksheep (Rep: 331) reply to blacksheepDate: 2017-04-24 08:05:37
Forum: Achaogen - Thread #673917298Msg #153 - Part 3/4 (Rec: 0)
Results from the Phase 3 EPIC study showed Achaogen's (NASDAQ:AKAO) plazomicin delivered better results than meropenem in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). The data were presented European Congress of Clinical Microbiology and Infectious Disease ((ECCMID)) in Vienna.
Plazomicin demonstrated superior microbiological eradication rates to meropenem in both groups, specifically a treatment advantage of 13.7% in cUTI and 17.5% in AP at test-of-cure. Patients receiving plazomicin also experienced a lower relapse rate, 1.8% versus 7.9%, than meropenem.
Results from the Phase 3 CARE study, investigating plazomicin compared to colistin combination therapy in patients with bloodstream infection (BSI) or hospital acquired or ventilator-associated bacterial pneumonia caused by carbapenem-resistant enterobacteriaceae (CRE) were also presented at ECCMID.
All-cause mortality for patients treated with plazomicin was 14.3% versus 53.3% in the colistin group (BSI).
The company plans to submit its U.S. marketing application in H2 and its application in Europe next year.
Previously: Achaogen's plazomicin successful in late-stage studies; U.S. marketing application on tap for H2 2017; shares up 22% premarket (Dec. 12, 2016)



PCYC ecx CEO ROBERT DUGGAN took stake=> Haven't sold any and have convert...
NOTE: This message has been revised 1 time. Read original version of this message.
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User blacksheep: Reward | Watch | Ignore

From: blacksheep (Rep: 331) reply to blacksheepDate: 2017-05-19 09:46:04
Forum: Achaogen - Thread #673917298Msg #156 - Part 4/4 (Rec: 0)
Some news: Achaogen's plazomicin successful in late-stage studies
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User blacksheep: Reward | Watch | Ignore


TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.